Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dementia with Lewy bodies.

Amos D Korczyn1, Heinz Reichmann

  • 1Sieratzki Chair of Neurology, Tel-Aviv University Medical School, Ramat-Aviv 69978, Tel-Aviv, Israel. neuro13@post.tau.ac.il

Journal of the Neurological Sciences
|October 13, 2006
PubMed
Summary

Dementia in advanced Parkinson's disease (PD) significantly impacts quality of life. Cholinesterase inhibitors offer limited benefits, and managing psychosis remains challenging due to safety concerns with neuroleptics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brainstem control of sleep, wakefulness, alertness, and consciousness.

Handbook of clinical neurology·2026
Same author

Prognostic Value of CSF Total Tau Protein in Patients with Familial and Sporadic Creutzfeldt-Jakob Disease.

Dementia and geriatric cognitive disorders·2026
Same author

Decline of Parkinson's Disease Incidence in Israel: The Value of Cohort Analysis.

Neuroepidemiology·2026
Same author

Declining incidence of Parkinson's disease in Israel (2002-2021).

Journal of neural transmission (Vienna, Austria : 1996)·2025
Same author

Limb-Kinetic apraxia of legs in Parkinson's disease: Prospective clinical investigation.

Clinical parkinsonism & related disorders·2025
Same author

Rethinking Parkinson's Disease: A Syndromic Perspective.

Movement disorders : official journal of the Movement Disorder Society·2024

Area of Science:

  • Neuroscience
  • Neurology
  • Geriatrics

Background:

  • Advanced Parkinson's disease (PD) frequently presents with dementia, impacting patient quality of life and survival.
  • The complex pathogenesis involves biogenic amine deficiency, Lewy body deposition, and co-existing Alzheimer-type or vascular brain changes.
  • Degeneration of cholinergic neurons in the nucleus basalis of Meynert is a significant contributor to cognitive decline in PD dementia.

Purpose of the Study:

  • To review the current understanding of dementia in advanced Parkinson's disease.
  • To evaluate the efficacy and limitations of cholinesterase inhibitors for PD dementia.
  • To discuss the challenges in managing psychosis (delusions and hallucinations) in demented PD patients.

Main Methods:

  • Literature review of studies on Parkinson's disease dementia.
  • Analysis of treatment outcomes for cholinesterase inhibitors.
  • Assessment of safety concerns regarding neuroleptics in PD patients with psychosis.

Main Results:

  • Cholinesterase inhibitors have shown gratifying, albeit limited, results in treating PD dementia.
  • Psychotic symptoms like delusions and hallucinations significantly distress patients and caregivers.
  • Safety concerns exist for both classical and novel neuroleptics in managing psychosis in PD patients.

Conclusions:

  • Further research is needed to define the precise role of cholinesterase inhibitors in PD dementia management.
  • There is a critical unmet need for safe and effective pharmacological treatments for psychosis in demented Parkinson's disease patients.

Related Experiment Videos